For the quarter ended June 2026, Ashland (ASH Quick QuoteASH - Free Report) reported revenue of $497 million, up 7.3% over the same period last year. EPS came in at $1.02, compared to $1.04 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $486.24 million, representing a surprise of +2.21%. The company delivered an EPS surprise of -0.97%, with the consensus EPS estimate being $1.03.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Ashland performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Intermediates: $37 million versus the three-analyst average estimate of $33.87 million. The reported number represents a year-over-year change of +12.1%.
• Revenue- Life Sciences: $180 million versus the three-analyst average estimate of $169.48 million. The reported number represents a year-over-year change of +11.1%.
• Revenue- Personal Care: $155 million compared to the $154.29 million average estimate based on three analysts. The reported number represents a change of +5.4% year over year.
• Revenue- Specialty Additives: $136 million compared to the $138.95 million average estimate based on three analysts. The reported number represents a change of +3.8% year over year.
• Revenue- Intersegment sales: $-11 million compared to the $-9.5 million average estimate based on two analysts. The reported number represents a change of +10% year over year.
• Adjusted EBITDA- Life Science: $60 million compared to the $55.43 million average estimate based on three analysts.
• Adjusted EBITDA- Personal Care: $45 million versus the three-analyst average estimate of $45.38 million.
• Adjusted EBITDA- Specialty Additives: $20 million versus $19.87 million estimated by three analysts on average.
• Adjusted EBITDA- Intermediates: $4 million versus the three-analyst average estimate of $3.71 million.
• OPERATING INCOME- Unallocated and other: $-37 million versus the two-analyst average estimate of $-16.5 million.

View all Key Company Metrics for Ashland here>>>

Shares of Ashland have returned +3.4% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.